Sylvia Benjamin
Overview
Explore the profile of Sylvia Benjamin including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
576
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Westwood J, Thomas M, Alwan F, McDonald V, Benjamin S, Lester W, et al.
Blood Adv
. 2018 Jan;
1(15):1159-1166.
PMID: 29296757
Acute antibody-mediated thrombotic thrombocytopenic purpura (TTP) is a thrombotic microangiopathy with high morbidity and mortality. Rituximab is highly effective as prophylaxis in patients at risk of acute TTP relapse, but...
2.
Alwan F, Vendramin C, Vanhoorelbeke K, Langley K, McDonald V, Austin S, et al.
Blood
. 2017 Jun;
130(4):466-471.
PMID: 28576877
Immune-mediated thrombotic thrombocytopenic purpura (TTP) is a life-threatening disorder caused by antibodies against ADAMTS13. From the United Kingdom TTP registry, we undertook a prospective study investigating the impact of the...
3.
Hassan S, Westwood J, Ellis D, Laing C, Mc Guckin S, Benjamin S, et al.
Br J Haematol
. 2015 Sep;
171(5):830-5.
PMID: 26359646
Thrombotic microangiopathies (TMAs) are frequently difficult to differentiate clinically, and measurement of ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) remains vital in thrombotic thrombocytopenic...
4.
Zhang W, Smythe J, Frith E, Belfield H, Clarke S, Watt S, et al.
Cytotherapy
. 2015 Aug;
17(9):1268-79.
PMID: 26276008
Background Aims: There is real and sustained interest in preparing T-regulatory cells from leukapheresis collections for cellular therapy through the use of simple, effective and reliable methods conforming to Good...
5.
Scully M, Hunt B, Benjamin S, Liesner R, Rose P, Peyvandi F, et al.
Br J Haematol
. 2012 May;
158(3):323-35.
PMID: 22624596
No abstract available.
6.
Hart D, Sayer R, Miller R, Edwards S, Kelly A, Baglin T, et al.
Br J Haematol
. 2011 Mar;
153(4):515-9.
PMID: 21391974
Thrombotic thrombocytopenic purpura (TTP) is an acute prothrombotic disorder. Human immunodeficiency virus (HIV) is an identified precipitant. This study reviewed 30 episodes of HIV-associated TTP in 24 patients from the...
7.
Scully M, Yarranton H, Liesner R, Cavenagh J, Hunt B, Benjamin S, et al.
Br J Haematol
. 2008 Jul;
142(5):819-26.
PMID: 18637802
Thrombotic thrombocytopenic purpura (TTP) is an acute, rare, life-threatening disorder. This report presents the South East (SE) England registry for TTP, from April 2002 to December 2006, which included 176...
8.
Scully M, Cohen H, Cavenagh J, Benjamin S, Starke R, Killick S, et al.
Br J Haematol
. 2007 Jan;
136(3):451-61.
PMID: 17233847
Thrombotic thrombocytopenic purpura (TTP) is a life-threatening disorder and plasma exchange (PEX) remains the primary treatment modality. Twenty-five patients with acute refractory/relapsing idiopathic TTP received rituximab in conjunction with PEX...
9.
Yarranton H, Cohen H, Pavord S, Benjamin S, Hagger D, Machin S
Br J Haematol
. 2003 Jun;
121(5):778-85.
PMID: 12780794
Venous thromboembolism (VTE) is not a feature of thrombotic thrombocytopenic purpura (TTP), but there has been a recent report of VTE in association with plasma exchange (PEX) treatment for TTP...